menu search

TSBX / Turnstone Biologics to offer 5.8 million shares in planned IPO priced at $12 to $14 each

Turnstone Biologics to offer 5.8 million shares in planned IPO priced at $12 to $14 each
Turnstone Biologics TSBX, , a clinical-stage biotech that specializes in treatments for solid tumors, set terms for its initial public offering on Monday with plans to offer 5.8 million shares priced at $12 to $14 each. The company would raise $81.2 million at the top of that range at a valuation of $298 million. Read More
Posted: Jul 17 2023, 06:35
Author Name: Market Watch
Views: 110886

TSBX News  

Turnstone Biologics set to go public as upsized $80 million IPO pricing at low end of expected range

By Market Watch
July 21, 2023

Turnstone Biologics set to go public as upsized $80 million IPO pricing at low end of expected range

Turnstone Biologics Corp. TSBX, is headed for its public debut Friday, as the San Diego-based biotechnology company focused on treating tumors raised more_horizontal

IPO Update: Turnstone Biologics Readies $75 Million IPO Plan

By Seeking Alpha
July 17, 2023

IPO Update: Turnstone Biologics Readies $75 Million IPO Plan

Turnstone Biologics Corp. has filed proposed terms for a $75.4 million IPO. The firm is developing drug treatment candidates for solid tumors and othe more_horizontal

Turnstone Biologics to offer 5.8 million shares in planned IPO priced at $12 to $14 each

By Market Watch
July 17, 2023

Turnstone Biologics to offer 5.8 million shares in planned IPO priced at $12 to $14 each

Turnstone Biologics TSBX, , a clinical-stage biotech that specializes in treatments for solid tumors, set terms for its initial public offering on Mon more_horizontal


Search within

Pages Search Results: